# BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence

> **Newsylist Open Intelligence Dossier** · First detected: 2026-10-13 18:29 UTC · Category: Business · Sources: 8 · Current Velocity: 6.36

## Intelligence Brief
"BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence" developed substantial multi-source reporting across the Business sector, tracked across 6 distinct newsrooms by Newsylist.


Key reporting was led by FirstWord Pharma, TradingView, GenomeWeb and CancerNetwork. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.


Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.

## Verified Facts & Key Claims
### What drove coverage for BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting an?
Coverage spiked when 6 independent newsrooms published 7 verified reports during this coverage cycle.

### How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| OncLive | Tenumomeran/Raplemomeran Plus Pembrolizumab Misses PFS End Point in HPV16+ HNSCC | 2026-10-13 12:48 | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxOQjduTEhJTVVodDJNZzREN3JJNkkzaTFHc2gybWhJalBoVTFjRVRhNGNlUHBqeVBaNUdzYUJNZ3JhWlp6TS1GTXNLUVBRS1I3eGVoYUZOeUlhZXA2cmlwSFBoMzlwX0lZTnllM2dBTV9INjQ1QUtSVk9VX2FOLUtLc284S2FwYkRXM3JxN2JKQ2JNNDRTMHkxdm10TkQtX2pTblQyV0lxeVBVV2t5?oc=5) |
| Yahoo Finance | BioNTech stock falls after cancer trial misses key endpoint | 2026-10-13 12:48 | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxQbmJqVjJNTW1VdzZHWHpyaUdLZHVsRW52QTBrQ01WT1hFYldDTUgzNm5lLUlyMXRzdDVVak1XTWhIZ1kxVThiQXVuUHVucWhwcVRKVzBqemFfR2hESnc5M05UZEVKNlZQcjRRNGVNeXByZy1Cdmh0ZkYyeWx4X1ZZWkRUU0tKTjRRMFVtRmtoS21zQmRvQUpUdjB3?oc=5) |
| FirstWord Pharma | BioNTech's HPV-targeted cancer vaccine misses PFS goal | 2026-10-13 12:48 | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTFA4dUFyeS1rd25UYmNxbklPenpFcDJ3ZWRqZF9rWWF0VHVUWUQ2QUpuVlhnN21JdlZsaHBNUWxib1pLSDdSemUtQWVGcmN2VmxfcmhZ?oc=5) |
| TradingView | BioNTech’s Cancer Drug Misses A Key Trial Goal – Citi Says Survival Data Could Preserve ‘A Meaningful Development Path’ | 2026-10-13 12:48 | [Source Link](https://news.google.com/rss/articles/CBMihwJBVV95cUxPMXZZbXNFeTFMaVZ0ckZwTzlRZzBpUGNIX0Y2SktZV3AtSUg2MFRkSmxENEVJcGZUSEQtWmYtVUpNTXZtVnFRbkVMbVN1TDRfMkpNZ1ZZWE5LQ1U5NnpJR0RnWkFSaWgyY2t0SmxPSHoyNFBPWDJZLTJWNVRuVGkzUllFYXg5UWlQMWlhYmFibzgyY2w0LWV6djdqMmdmU3JPbWVIemgyaXdrWVdWb2dPc3ZDNDFJa1NYZnhHbmJadlV0a09UbHFTVU9EWXk4V2pQY21BRGNsVUZiMjVGenMzeUJLRlpaSk5uVE9DTVJrT2M5Q0VkT0VmTi1Udy1obDNCSnpsbjBMaw?oc=5) |
| TradingView | BioNTech's mRNA cancer therapy misses first goal in head and neck trial | 2026-10-13 12:48 | [Source Link](https://news.google.com/rss/articles/CBMi2AFBVV95cUxOQkpUaXRhY2JBNDR3Mk05VmN4SmtNSUlBMkF5TG16d3llUERPMlRGeGpaLWRoXzdHWkRoUFlHdTVFOGV0S055MHV4dmg4d0J6UDFKVmprM2dtSVBaQmE1ZDdIN2d0ODk2X1Qtem9WTzM1YkxoQWhOeFFoNkFMaHZTUW1teGVaUGgwVk9LQmJiNkNsczRFRDVGUnk5UWs1MGpwaDNtQ0xuX3NuSmdlempzaUZFeUdYenlhOGhOQUFCb2c3TEt5N3R3a3JqYjNQVlVyTnFuZGc0NWE?oc=5) |
| GenomeWeb | BioNTech mRNA Trial Will Keep Tracking Overall Survival After Initial Progress-Free Survival Failure | 2026-10-13 12:48 | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxPenRGdjBSS1VnZ202SzNVLXRYcnpGbi1LRmxPV0VJZ3JwZmJFSjBEOC1zMVU4V1h4VjJVUERFWlJzMWRCaGpOb3Y2YmtPQ2pYR2RDa3ROY254c254UHViQy0zNWZIdld6YUxlZHZRVnJycVJHNkNDNVZiQzJUNWNlbGd3MGVvQTRqLTUyZW85cVhyT0xKT2hnZzBaUW0wUzZxUFNLZ3lDc29FZldR?oc=5) |
| CancerNetwork | BNT113/Pembrolizumab Misses PFS End Point in HPV16+ Head and Neck Cancer | 2026-10-13 12:48 | [Source Link](https://news.google.com/rss/articles/CBMiqgFBVV95cUxQc1VuMmtnSDZtNjJVV2R0NS1hdU5QSVdMcUgweW5qRnlIQ3kwazN6NWluX0dYbmc1M1p4SFk2UzFNRUJsMDA0N2w1cHgtVDljSkVKUzRncmxScnpnNzlldFpVTnBuSUliYTBESmZiakZfUVhPamgtVWY3WmJkZU1VbldlRFpJWmRTYUVqUWxxbEZhTTlqMjgxZE9ocjBUNGhUSGlvTTk4VTVGQQ?oc=5) |
| Bloomberg.com | BioNTech Says Cancer Treatment Didn’t Help in Early Analysis | 2026-10-13 12:48 | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxOSHI1X2ZCM0E4cUVTVWlIUUZNVWQ3VElHVGpKRkprUG03MlRTb0t6a3pnd2xxWEhlbFk0bWpLUVNiaGZnR294Q2ZQVERnTkxFSmFMWVNUbzRwZDhKWm9UQnk0dlYxdzhveDUtYmlVVm1DZ2FkMFBjbzIyUGNpQktGcF9Pb1lBQkNIbXY5R08tT2lEeUswUXhkR0g4WnNHd3lUeUhTZi0tRUFPUXlrNmtuUw?oc=5) |
| Fierce Biotech | BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence | 2026-10-13 12:48 | [Source Link](https://news.google.com/rss/articles/CBMixwFBVV95cUxOaVZuRk1zMFhhQmhFQmZVak0zXzV5NjFfTGtWVGFaYnVJVk1EbG42eGFpaHp1eVNRam4zaHE0aDZ6eHhtcU5MRlBqVXRPc2dWdHdYS3pMOUlaUlBvRXhOcmZrNDExRllBWjZ3Nm1pRTRud3NETzFHOWlmWWc3NTM4YmhoMGcwTkJBYXB2MHNmR0poWWEyRklkWXdONDdZbXhTYXEzalJfRER1TmJ5d1I3M3BUdy02aTMxVWlPbS1PTW9haVpTWGFZ?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-10-13/biontech-s-mrna-cancer-vaccine-fails-phase-3-test-significantly-denting*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*